Business, energy, technology, markets and global industry news from Business News Today

RNA interference

PharmaDeviceNews RNA interference
Ribo and Madrigal have advanced their first siRNA drug candidate for MASH into IND-enabling studies, highlighting the growing role of gene-silencing therapies in liver disease treatment. Representative image.
Pharma & Biotech

Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation

Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.

Read More
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More
Pharma & Biotech

Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?

Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.

Read More
Pharma & Biotech

How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows

Explore why Codexis, Inc.’s latest RNA manufacturing advances could influence scalability, stereochemical control, and future siRNA production economics.

Read More
Representative image: Arrowhead Pharmaceuticals’ REDEMPLO approval in Australia highlights the growing role of RNAi therapies in treating familial chylomicronemia syndrome and severe triglyceride disorders.
Pharma & Biotech

Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now

Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.

Read More
Pharma & Biotech

Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe

Plozasiran clears CHMP but the real test is reimbursement. Europe's HTA bodies will now decide whether clinical FCS diagnosis is enough.

Read More
Pharma & Biotech

Can Arrowhead Pharmaceuticals expand plozasiran without the Ionis patent fight becoming a commercial overhang?

Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.

Read More
Pharma & Biotech

How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran

See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.

Read More
Pharma & Biotech

Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data

Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.

Read More
Representative image of rare disease drug research as Sarepta Therapeutics unveils early SRP-1001 and SRP-1003 clinical data in FSHD1 and DM1, a key moment for its siRNA pipeline beyond Duchenne.
Pharma & Biotech

Can Sarepta Therapeutics prove RNA interference works in FSHD1 and DM1 with early Phase 1/2 data

Read why Sarepta Therapeutics’ first siRNA data in FSHD1 and DM1 could matter for rare disease drug development and investor sentiment.

Read More